Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab + niraparib in advanced ovarian cancer
NCT03602859Phase 3Active, not recruiting
- Start
- Oct 2018
- Primary completion
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of dostarlimab in ovarian cancer (3 arms). Primary endpoint: Progression-Free Survival at 316 weeks. Started Oct 2018; status: active, not recruiting.
02
Drugs
dostarlimab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03602859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602859.